节点调节器通过Chk2通路调节肺癌中的化学和放射电阻
Hye Min Kim1,2, Ju-Young Kim3,4, Chang Geun Lee1
1Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, Republic of Korea.
Anticancer research
|October 28, 2025
概括
节点调节器 (NOMO) 驱动肺癌对化疗和放射治疗的抗性. 沉默NOMO通过促进细胞亡和影响Chk1/Chk2激酶来恢复敏感性,这表明NOMO是基因治疗的目标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 肺癌治疗疗效受到化疗和放射电阻的限制.
- 节点调节器 (NOMO1-3) 与放射电阻有关.
- 诺莫蛋白在肺癌中表达高,但其功能尚不清楚.
研究的目的:
- 为了确定NOMO在肺癌中的功能.
- 为了调查NOMO在化疗和放射电阻中的作用.
主要方法:
- 使用了人类NOMO特定的小干扰RNA (siRNA).
- 评估NOMO沉默对瘤细胞活力和亡的影响.
- 采用抗体阵列来分析蛋白质酸化.
主要成果:
- 通过NOMO沉默,通过酶依赖的亡来逆转化疗和放射电阻.
- 诺莫抑制增加了检查点激酶Chk1和Chk2的酸化.
- Chk1和Chk2调节化学和辐射电阻.
结论:
- 诺莫和Chk2通路是肺癌化疗和放射电阻的关键参与者.
- 诺莫代表了肺癌基因治疗的潜在治疗标.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
564
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
564
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Positive Regulator Molecules
6.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.5K


